文献速递淋巴瘤造血干细胞移植与细胞治疗

氟达拉滨暴露对大B细胞淋巴瘤CAR-T疗效的影响

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

这项前瞻性单中心研究纳入54例复发/难治性大B细胞淋巴瘤患者,在清淋期间用群体药代动力学模型估算氟达拉滨AUC,发现不同CAR-T产品各有最佳暴露窗,处于窗内者无进展生存显著更优。

要点

  • axi-cel最佳氟达拉滨AUC窗为17.5–21.5 mg·h/L,tisagenlecleucel为14.0–18.0 mg·h/L。
  • 处于最佳暴露窗者中位PFS未达到,窗外者为13.3个月(P = .03)。
  • 多变量分析中最佳暴露独立关联PFS改善(P = .03),支持PK指导给药。

核心结论

  • 清淋期间氟达拉滨暴露存在与CAR-T产品相关的最佳AUC窗,窗内患者PFS更长。
  • 结果支持整合药代动力学指导的氟达拉滨给药以改善治疗结局。

研究设计与样本

  • 前瞻性、单中心研究,纳入54例接受商业化CD19 CAR-T治疗的复发/难治性大B细胞淋巴瘤患者。
  • 清淋期间按预设时间点最多采集7份血浆样本,用群体PK模型估算氟达拉滨AUC。
  • 采用迭代立方样条法确定各CAR-T产品特异的最佳AUC暴露范围,主要终点为PFS。

主要发现

  • 中位随访24.5个月,中位氟达拉滨AUC为18.12 mg·h/L(四分位距14.56–20.55)。
  • 最佳暴露窗为axi-cel 17.5–21.5 mg·h/L、tisagenlecleucel 14.0–18.0 mg·h/L,24例(44%)处于窗内。
  • 最佳暴露组CAR-T输注后中位PFS未达到,其他组为13.3个月(P = .03)。
  • 多变量分析中最佳暴露独立关联PFS改善(P = .03),axi-cel治疗亦独立关联PFS改善(P = .03)。
  • 两组CAR-T扩增及任何级别细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和血液毒性发生率相似。

关键数值与推荐

  • axi-cel最佳氟达拉滨AUC窗为17.5–21.5 mg·h/L。
  • tisagenlecleucel最佳氟达拉滨AUC窗为14.0–18.0 mg·h/L。
  • 最佳暴露组中位PFS未达到,其他组13.3个月(P = .03)。

临床怎么用

  • 对接受CD19 CAR-T治疗的复发/难治性大B细胞淋巴瘤患者,可考虑监测氟达拉滨暴露。
  • 按CAR-T产品对应的最佳AUC窗进行PK指导的氟达拉滨剂量调整,以延长PFS。

局限性

  • 单中心、前瞻性研究,样本量54例,结论需外部验证。
  • 最佳暴露窗由迭代立方样条法得出,属探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of fludarabine pharmacokinetics (PK) on chimeric antigen receptor (CAR) T-cell outcomes is not fully elucidated. We hypothesized that in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), measured fludarabine exposure during lymphodepletion would correlate with CAR T-cell results. We conducted a prospective, single-center study including patients with R/R LBCL treated with commercial, CD19-targeted CAR T-cell products. Up to 7 plasma samples per patient were collected at predefined intervals during lymphodepletion. Fludarabine exposure (area under the curve [AUC]) was estimated using a population PK model. An iterative cubic spline approach identified optimal AUC exposure ranges specific to each CAR T-cell product. The primary end point was progression-free survival (PFS). Among 54 patients with a median follow-up of 24.5 months, the median fludarabine AUC was 18.12 mg·h/L (interquartile range, 14.56-20.55). Optimal exposure windows were 17.5 to 21.5 mg·h/L for axicabtagene ciloleucel (axi-cel) and 14.0 to 18.0 mg·h/L for tisagenlecleucel, with 24 patients (44%) inside these ranges. Median PFS after CAR T-cell infusion was not reached vs 13.3 months in the optimal vs other cohort (P = .03). In the multivariable analysis, optimal exposure remained independently associated with improved PFS (P = .03), together with axi-cel treatment (P = .03). CAR T-cell expansion and rates of any grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and hematotoxicity were similar between groups. In conclusion, the prospective measurement of fludarabine exposure identified an optimal AUC window associated with prolonged PFS in patients with R/R LBCL receiving CAR T-cell therapy. These findings support the integration of PK-guided fludarabine dosing to enhance therapeutic outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sánchez-Salinas MA, Varela-González-Aller J, Iacoboni G, et al. Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. Blood Adv. 2026. PMID: 42269079. doi:10.1182/bloodadvances.2025019264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。